HUP0001960A2 - Metotrexát kombináció autoimmun tünetek befolyásolására - Google Patents

Metotrexát kombináció autoimmun tünetek befolyásolására

Info

Publication number
HUP0001960A2
HUP0001960A2 HU0001960A HUP0001960A HUP0001960A2 HU P0001960 A2 HUP0001960 A2 HU P0001960A2 HU 0001960 A HU0001960 A HU 0001960A HU P0001960 A HUP0001960 A HU P0001960A HU P0001960 A2 HUP0001960 A2 HU P0001960A2
Authority
HU
Hungary
Prior art keywords
methotrexate
administered
autoimmune disease
tolerization
treatment
Prior art date
Application number
HU0001960A
Other languages
English (en)
Inventor
Ahmad Al-Sabbagh
Patricia A. Nelson
Howard L. Weiner
Original Assignee
Autoimmune, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autoimmune, Inc. filed Critical Autoimmune, Inc.
Publication of HUP0001960A2 publication Critical patent/HUP0001960A2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
    • B41J—TYPEWRITERS; SELECTIVE PRINTING MECHANISMS, i.e. MECHANISMS PRINTING OTHERWISE THAN FROM A FORME; CORRECTION OF TYPOGRAPHICAL ERRORS
    • B41J2/00—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed
    • B41J2/005—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed characterised by bringing liquid or particles selectively into contact with a printing material
    • B41J2/01—Ink jet
    • B41J2/21—Ink jet for multi-colour printing
    • B41J2/2107—Ink jet for multi-colour printing characterised by the ink properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
    • G06K2215/00—Arrangements for producing a permanent visual presentation of the output data
    • G06K2215/0082—Architecture adapted for a particular function
    • G06K2215/0094—Colour printing
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
    • G06K2215/00—Arrangements for producing a permanent visual presentation of the output data
    • G06K2215/0082—Architecture adapted for a particular function
    • G06K2215/0097—Printing on special media, e.g. labels, envelopes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A találmány bystander antigén és metotrexát autoimmun betegség ellenható gyógyászati készítmény előállítására történő alkalmazásáravonatkozik, ahol a komponensek külön-külön vagy egymást követőadagolása esetében a bystander antigént gyógyászatilag elfogadhatóformában orálisan, enterálisan vagy inhalálás útján és a metotrexátotgyógyászatilag elfogadható formában orálisan vagy parenterálisanadagolják, és a két komponens ugyanazon készítményben valóadagolásakor mindkettőt enterálisan vagy orálisan adagolják. Atalálmány tárgyát képezi a metotrexátot és a bystander antigént vagyautoantigént tartalmazó gyógyászati készítmény és kit előállításieljárása is. Ó
HU0001960A 1997-01-24 1998-01-26 Metotrexát kombináció autoimmun tünetek befolyásolására HUP0001960A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3672297P 1997-01-24 1997-01-24
PCT/US1998/001648 WO1998032451A1 (en) 1997-01-24 1998-01-26 Treatment of autoimmune disease using tolerization in combination with methotrexate

Publications (1)

Publication Number Publication Date
HUP0001960A2 true HUP0001960A2 (hu) 2000-10-28

Family

ID=21890248

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0001960A HUP0001960A2 (hu) 1997-01-24 1998-01-26 Metotrexát kombináció autoimmun tünetek befolyásolására

Country Status (10)

Country Link
EP (1) EP0994717A4 (hu)
JP (1) JP2001511134A (hu)
KR (1) KR20000070460A (hu)
AU (1) AU6648898A (hu)
BR (1) BR9807112A (hu)
CA (1) CA2278152A1 (hu)
HU (1) HUP0001960A2 (hu)
IL (1) IL131025A0 (hu)
NO (1) NO993600L (hu)
WO (1) WO1998032451A1 (hu)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040103930A (ko) 2002-02-11 2004-12-09 앤태어스 파머, 인코퍼레이티드 피내 주사기
BRPI0614025A2 (pt) 2005-01-24 2012-12-25 Antares Pharma Inc injetores de jato
GB0523576D0 (en) * 2005-11-18 2005-12-28 Theradeas Ltd Drug composition and its use in therapy
US8251947B2 (en) 2006-05-03 2012-08-28 Antares Pharma, Inc. Two-stage reconstituting injector
US9144648B2 (en) 2006-05-03 2015-09-29 Antares Pharma, Inc. Injector with adjustable dosing
EP2268342B1 (en) 2008-03-10 2015-09-16 Antares Pharma, Inc. Injector safety device
JP5611208B2 (ja) 2008-08-05 2014-10-22 アンタレス・ファーマ・インコーポレーテッド 多数回服用量の注射装置
AU2010226442A1 (en) 2009-03-20 2011-10-13 Antares Pharma, Inc. Hazardous agent injection system
EP2582373A4 (en) 2010-06-16 2013-10-30 Bruce Chandler May USE OF LEVOCETIRIZIN AND MONTELUKAST IN THE TREATMENT OF INFLUENZA, COLLECTIONS AND INFLAMMATION
US9220660B2 (en) 2011-07-15 2015-12-29 Antares Pharma, Inc. Liquid-transfer adapter beveled spike
US8496619B2 (en) 2011-07-15 2013-07-30 Antares Pharma, Inc. Injection device with cammed ram assembly
JP6165786B2 (ja) 2012-03-06 2017-07-19 アンタレス・ファーマ・インコーポレーテッド 離脱力特徴を備える充填シリンジ
CN104487114A (zh) 2012-04-06 2015-04-01 安塔雷斯药品公司 针头辅助喷射注射给予睾酮组合物
WO2013169800A1 (en) 2012-05-07 2013-11-14 Antares Pharma, Inc. Injection device with cammed ram assembly
EP2953667B1 (en) 2013-02-11 2019-10-23 Antares Pharma, Inc. Needle assisted jet injection device having reduced trigger force
WO2014164786A1 (en) 2013-03-11 2014-10-09 Madsen Patrick Dosage injector with pinion system
WO2014165136A1 (en) 2013-03-12 2014-10-09 Antares Pharma, Inc. Constant volume prefilled syringes and kits thereof
CA2901413A1 (en) 2013-03-13 2014-10-09 Bruce Chandler May Use of levocetirizine and montelukast in the treatment of vasculitis
RU2672871C2 (ru) 2013-03-13 2018-11-20 Инфламматори Респонс Ресёрч, Инк. Применение левоцетиризина и монтелукаста при лечении травматических повреждений
RU2015134423A (ru) * 2013-03-13 2017-04-26 Инфламматори Респонс Ресёрч, Инк. Применение левоцитиризина и монтелукаста при лечении аутоиммуных расстройств
EP3193875B1 (en) 2014-09-15 2022-02-16 Inflammatory Response Research, Inc. Levocetirizine and montelukast in the treatment of inflammation mediated conditions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE258065T1 (de) * 1987-06-24 2004-02-15 Brigham & Womens Hospital Behandlung von autoimmun-erkrankungen durch orale verabreichung von autoantigenen
US5571500A (en) * 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases through administration by inhalation of autoantigens
US5571499A (en) * 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
WO1992004049A1 (en) * 1990-09-06 1992-03-19 Rijksuniversiteit Te Utrecht Inhibitor of lymphocyte response and immune-related disease
BR9306042A (pt) * 1992-02-28 1997-11-18 Autoimmune Inc Método para tratar uma doença auto-immune em um mamifero e formas de dosagens farmacêuticas oral e inalável
WO1996040235A1 (en) * 1995-06-07 1996-12-19 Nexstar Pharmaceuticals, Inc. Method to use superantigens to target subpopulations of t cells
EP0834321B1 (en) * 1995-06-13 2003-05-02 Nippon Meat Packers, Inc. Oral remedy for rheumatoid arthritis and functional food

Also Published As

Publication number Publication date
NO993600L (no) 1999-09-23
IL131025A0 (en) 2001-01-28
NO993600D0 (no) 1999-07-23
AU6648898A (en) 1998-08-18
EP0994717A1 (en) 2000-04-26
CA2278152A1 (en) 1998-07-30
BR9807112A (pt) 2001-09-18
EP0994717A4 (en) 2000-07-26
JP2001511134A (ja) 2001-08-07
KR20000070460A (ko) 2000-11-25
WO1998032451A1 (en) 1998-07-30

Similar Documents

Publication Publication Date Title
HUP0001960A2 (hu) Metotrexát kombináció autoimmun tünetek befolyásolására
Ross et al. The development and progression of subacute combined degeneration of the spinal cord in patients with pernicious anemia treated with synthetic pteroylglutamic (folic) acid
DK0613371T3 (da) Ny kombination af formoterol og budesonid
HUP0100627A1 (hu) Amiloidogén betegségek megelőzése és kezelése
HU9502065D0 (en) Application of carbamazepine and oxcarbazepine in the treatment of parkinson's disease and parkinsonian syndromes
FR2721516B1 (fr) Nouvelles utilisations d'un complexe à base de phospholipides cérébraux en thérapeutique et dans l'alimentation.
NZ542866A (en) Compositions and methods for the therapy of inflammatory bowel disease
HUP0202525A2 (hu) Mofetil mikofenolát és PEG-IFN-alfa együttes alkalmazása, valamint az azokat tartalmazó gyógyszerkészítmények és kit
HUP0204391A2 (en) The use of mirtazapine for the preparation of pharmaceutical composition suitable for the treatment of sleep disorders
MD970254A (en) Use of melatonine for treatment of patients having a medicamental dependence
Welch Chicken-pox and the Guillain Barré Syndrome
Clayman et al. Ankylosing spondylitis with subsequent development of rheumatoid arthritis, Sjögren's syndrome, and rheumatoid vasculitis
ES2038847T3 (es) Proceso para la preparacion de una composicion farmacutica conteniendo zidovudine e inosiplex para el tratamiento del sida y sindromes afines.
Basso et al. Ideomotor apraxia arising from a purely deep lesion.
CA2318424A1 (en) Use of odorants to alter vaginal blood flow, and article of manufacture therefor
McDonald et al. Focal upper limb neuropathy in a child
Winkelman et al. Prostigmin in the Treatment of Myasthenia Gravis and Muscular Dystrophy: Results Obtained with Divided Doses
RG Chicken-pox and the Guilain Barre syndrome.
孙丽琴 TREATMENT OF RHEU MATOID ARTHRITIS BY WARMING NEEDLE
WO1989002745A1 (en) Pharmaceutical preparation for curing multiple sclerosis and lateral amyotrophic sclerosis
CROCKER et al. Gas gangrene infection, antitoxin, and serum neuritis
Scime Abstinence Only Answer For Teen Contraception
郭天文 Studies on Protrusive Balanced Occlusion of Complete Denture
RU93032284A (ru) Способ лечения заболевания легких
BR0009646A (pt) Terapia de melanoma